ABUS Arbutus Biopharma Corp
Pharmaceutical Preparations · Nasdaq · SEC CIK 1447028 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1,142.6%
TTM net income YoY620.2%
TTM EPS YoY587.0%
Revenue 3-yr CAGR101.3%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin81.1%
Net margin121.2%
FCF margin—
EBITDA margin81.1%
Returns
ROE269.6%
ROA100.6%
ROIC (approx.)—
Asset turnover0.83x
Leverage & solvency
Liabilities / assets74.8%
Debt / equity0.00x
Current ratio1.40x
Interest coverage2,299.38x
Cash quality & payout
Operating cash flow / net income1.00x
Accruals ratio-0.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $14.08M | $6.17M |
| R&D expense | $25.24M | $54.04M |
| SG&A expense | $15.89M | $22.11M |
| Operating income | -$38.16M | -$76.32M |
| Interest expense | $97,000 | $137,000 |
| Pretax income | $11.95M | -$1.67M |
| Income tax | $0 | $0 |
| Net income | -$33.50M | -$69.92M |
| EBITDA | -$37.80M | -$74.94M |
| EPS (basic) | -0.17 | -0.38 |
| EPS (diluted) | -0.17 | -0.38 |
| Weighted avg. shares (diluted) | 191.60M | 185.61M |
| Balance sheet | ||
| Cash & equivalents | $18.01M | $36.33M |
| Short-term investments | $73.46M | $86.29M |
| Receivables | $1.45M | $2.41M |
| Current assets | $94.46M | $127.32M |
| PP&E, net | $32,000 | $3.31M |
| Total assets | $94.62M | $131.71M |
| Current liabilities | $6.01M | $15.62M |
| Long-term debt | $0 | $0 |
| Total debt | $0 | $0 |
| Total liabilities | $18.04M | $34.34M |
| Shareholders' equity | $76.58M | $97.37M |
| Net debt | -$18.01M | -$36.33M |
| Shares outstanding | 192.53M | 189.96M |
| Cash flow statement | ||
| Operating cash flow | -$39.64M | -$64.85M |
| Capital expenditure | $0 | $182,000 |
| Free cash flow | -$39.64M | -$65.03M |
| Investing cash flow | $15.58M | $22.95M |
| Financing cash flow | $5.72M | $52.00M |
| Depreciation & amortization | $363,000 | $1.38M |
| Stock-based compensation | $6.95M | $8.99M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.